Wutah pendapatan kuartal marang kuartal: DURECT Corp (DRRX)

durect.com (DRRX) - logo korporat

DURECT Corporation develops liver therapy medications, focusing on patients with alcoholic hepatitis and the drug Larsucosterol. Quarterly sales dynamics reflect current trends, with the value stabilizing at -79.60. However, a lack of profitability and high R&D expenses are creating a serious liquidity deficit. The company's prospects rely on Larsofanel, which is capable of blocking inflammation genes without the need for an organ transplant.

DRRX (DURECT Corp.) riwayat Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 27.09.2025

durect.com (DRRX) - rincian metrik lan laporan keuangan

- indikator dhuwit lan arus kas:
Analisis umum perusahaan:DURECT Corp. (DRRX)
Barang unggulan DURECT Corporation

Investors must evaluate the asset's fundamental stability by analyzing sales growth rates, which drive liquidity inflows and market momentum. This quarterly revenue chart reveals business acceleration phases, which for DURECT Corporation (DRRX) is confirmed by the retention of key biochemists and experts ensuring the steady development of long-term projects in liver disease therapy.